MedTrace Logo

Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML

NCT04887259 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2025-01-27

No results posted yet for this study

Summary

A phase 1, first-in-human trial to evaluate the safety and tolerability of LAVA-051 in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), or Acute Myeloid Leukemia (AML).

Conditions

Interventions

BIOLOGICAL

LAVA-051

In part 1 and part 2, LAVA-051 will be administered via intravenous (IV) infusion

BIOLOGICAL

Interleukin 2

In Part 1 and Part 2, a low dose of interleukin 2 will be given via subcutaneous injection with LAVA-051 in a selected group of patients

Sponsors & Collaborators

  • Lava Therapeutics

    lead INDUSTRY

Principal Investigators

  • Clinical Trials Management · Lava Therapeutics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-12
Primary Completion
2023-09-06
Completion
2023-09-06
FDA Drug
Yes

Countries

  • United States
  • France
  • Netherlands
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04887259 on ClinicalTrials.gov